RxDoctor Payments Data

Hajar Ayoub, MD

Urology · Houston, TXNPI 1902232846

Payments from drug & device makers

$5,946in general payments, 2019–2025

Across 159 payments — averaging $37.40 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boston Scientific$1K
  • Medtronic$1K
  • Axonics, Inc.$782
  • Angiodynamics, Inc.$553
  • AbbVie$421
  • Johnson & Johnson$411
  • plus $2K from 17 others

What the payments were for

  • Travel & lodging$1292%
  • Food & beverage$5,69196%
  • Education$1262%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Boston Scientific27$1,130
Medtronic(2 entities)16$1,035
Axonics, Inc.22$782
Angiodynamics, Inc.18$553
AbbVie(2 entities)23$421
Johnson & Johnson(3 entities)7$411
Cook Medical LLC5$328
Ambu Inc.2$190
Astellas Pharma US Inc4$163
Coloplast3$138
Hollister Incorporated5$119
Conmed Corporation1$118
Convatec Inc.5$97
Sumitomo Pharma America, Inc.4$83
Urovant Sciences Inc4$76
C. R. Bard, Inc. & Subsidiaries3$75
180 Medical, Inc.3$59
Stryker1$46
Olympus America Inc.2$37
Laborie Medical Technologies Corp.1$27
ABC Home Medical Supply, Inc.1$24
RGH Enterprises LLC1$18
Endo Pharmaceuticals Inc.1$16

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,946 in reported general payments places this provider in the 60th percentile of 878 urology providers in Texas.

See all urology providers in Texas

Medicare billing

Part B allowed, 2024
$52,632
Medicare patients
147
Services billed
801

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
GemtesaVibegron64$57,558
MyrbetriqMirabegron47$26,164
Estradiol36$2,857
Finasteride50$286
Tamsulosin Hcl46$259
Alfuzosin Hcl ErAlfuzosin Hcl13$195

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Sumitomo Pharma America, Inc.Gemtesa$83$57,55864 claims
Astellas Pharma US IncMyrbetriq$163$26,16447 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 878 urology providers in Texas.

Other urology in Houston

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →